Sandy Spring Bank’s Viking Therapeutics VKTX Stock Holding History

Sandy Spring Bank’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$3.26K	Sell	135 -50	-27%	-$1.58K	﹤0.01%	989
2024 Q4	$7.45K	Buy	185 +50	+37%	+$2.85K	﹤0.01%	907
2024 Q3	$8.55K	Hold	135	–	–	﹤0.01%	885
2024 Q2	$7.16K	Hold	135	–	–	﹤0.01%	933
2024 Q1	$11.1K	Sell	135 -15	-10%	-$667	﹤0.01%	837
2023 Q4	$2.79K	Hold	150	–	–	﹤0.01%	984
2023 Q3	$1.66K	Hold	150	–	–	﹤0.01%	1045
2023 Q2	$2.43K	Hold	150	–	–	﹤0.01%	1047
2023 Q1	$2.5K	Sell	150 -100	-40%	-$1.03K	﹤0.01%	1010
2022 Q4	$2.35K	Hold	250	–	–	﹤0.01%	1005
2022 Q3	$1K	Hold	250	–	–	﹤0.01%	1112
2022 Q2	$1K	Hold	250	–	–	﹤0.01%	1111
2022 Q1	$1K	Hold	250	–	–	﹤0.01%	1108
2021 Q4	$1K	Hold	250	–	–	﹤0.01%	1197
2021 Q3	$2K	Hold	250	–	–	﹤0.01%	1080
2021 Q2	$1K	Hold	250	–	–	﹤0.01%	1124
2021 Q1	$2K	Sell	250 -90	-26%	-$633	﹤0.01%	956
2020 Q4	$2K	Buy	+340	New	+$2.06K	﹤0.01%	900

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sandy Spring Bank's VKTX Position: Q1 2025 in Review

Sandy Spring Bank reduced its Viking Therapeutics (VKTX) stake by 27% in Q1 2025, selling an estimated $1.58K and leaving 135 shares worth $3.26K. The position accounts for ﹤0.01% of the portfolio, ranked #989.

Sandy Spring Bank first reported a position in VKTX in Q4 2020 and has held it in 18 quarters since. The position peaked at $11.1K in Q1 2024. 372 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

Sandy Spring Bank held 135 shares of Viking Therapeutics worth $3.26K as of Q1 2025.
Sandy Spring Bank sold 50 Viking Therapeutics shares in Q1 2025, an estimated $1.58K.
Viking Therapeutics made up ﹤0.01% of Sandy Spring Bank's portfolio in Q1 2025, its #989 holding.
Sandy Spring Bank first reported a position in Viking Therapeutics in Q4 2020 and has held it in 18 quarters since.
Sandy Spring Bank's Viking Therapeutics position peaked at $11.1K in Q1 2024.
372 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on Sandy Spring Bank's 13F filing for Q1 2025, filed 12 May 2025.